$7.68
arrow_drop_up1.45%Key Stats | |
---|---|
Open | $7.59 |
Prev. Close | $7.56 |
EPS | -0.43 |
Dividend | Non-Dividend |
Next Earnings Date | - |
Dividend Yield % | - |
PE Ratio | - |
LOW | HIGH | |
---|---|---|
Day Range | 7.59 | 8.56 |
52 Week Range | 1.05 | 6.15 |
Ratios | |
---|---|
Revenue | - |
EBITDA Margin % | - |
EPS | -0.43 |
Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.
Period: Next 12 Months
•Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.
Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2024 Financial Results
Corvus Pharmaceuticals to Provide Business Update and First Quarter 2024 Financial Results on May 6, 2024
Corvus Pharmaceuticals Announces Pricing of $30.6 Million Registered Direct Offering
Here's Why Corvus (CRVS) is Poised for a Turnaround After Losing -25% in 4 Weeks
Corvus Pharmaceuticals Announces Initiation of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis
Down -18.35% in 4 Weeks, Here's Why Corvus (CRVS) Looks Ripe for a Turnaround